The main objective of this prospective, open-label clinical trial is to assess the effectiveness and safety of intra-articular liposomal gel therapy for knee OA symptoms.

Inclusion Criteria:

• Age between 38 and 70 years,
• OA diagnosed by the American College of Rheumatology (ACR) criteria,
• OA diagnosed by radiographic imaging (grade II - III according to the Kellgren-Lawrence scale),
• Pain in the knee joint for at least 3 months,
• Screening pain intensity in the target knee measured on VAS scale was required to be 4 for symptomatic knee and 2 for the contralateral knee.

Exclusion Criteria:

• Previous injections of hyaluronic acid or platelet-rich plasma within 6 months or corticosteroid injections within 3 months before the enrollment,
• Present joint infection,
• Previous knee arthroscopy up to 1 year prior to examination,
• Peripheral inflammatory and autoimmune diseases that progress with joint involvement (rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematosus etc.),
• Total arthroplasty and osteotomy,
• Ankylosis of the study joint,
• Dermatitis or dermatological disease at the intended injection site,
• Known hypersensitivity to the components of the preparation,
• Coexistence of the degenerative changes in other limb joints (hip, foot),
• Cancer,
• Oral corticosteroid therapy,
• Use of medicines that affect blood clotting (heparins, oral anticoagulants, thrombolytic drugs),
• Pregnancy or breast-feeding.
• History of injury to the knee, a broken bone or dislocation of a joint, other musculoskeletal diseases that affect the study joint, neoplastic disease.
• Participation in other clinical trials.